FDA-cleared profile

Dose+ (1.0)

Mvision AI Oy · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.

Clinical role
Pre-optimization dose guidance transferred to a treatment-planning system or DICOM-RT viewer for professional review.
Images and patients
Radiotherapy Planning Imaging · Prostate/Pelvis
Key limitation
Keep in mind: Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Prostate/Pelvis Input: Patient CT images, RT Structure Sets, ROI names, and target dose prescription.
  • Who uses it?Intended users: Qualified radiation oncologists, medical physicists, and medical dosimetrists.
  • What does the software produce?Output: DICOM RT Dose object containing a predicted three-dimensional dose distribution.
  • What is its most important limitation?Key limitation: Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.

Clinical takeaway. Clinical role: Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.

Evidence takeaway. Evidence from the reviewed source record: FDA materials describe separate development, independent performance-verification, and four-site prospective U.S. clinical-validation datasets. Both prostate and pelvic-node models met predefined plan-quality, optimization-iteration, user-acceptance, and safety criteria; the summary does not publish all sample sizes or effect estimates.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.
  • Exact FDA submission
  • Checked 2026-09-04

Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.

Workflow role
Pre-optimization dose guidance transferred to a treatment-planning system or DICOM-RT viewer for professional review.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Patient CT images, RT Structure Sets, ROI names, and target dose prescription.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
DICOM RT Dose object containing a predicted three-dimensional dose distribution.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Radiation-therapy planning departments in hospitals and clinics.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified radiation oncologists, medical physicists, and medical dosimetrists.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
FDA materials describe separate development, independent performance-verification, and four-site prospective U.S. clinical-validation datasets. Both prostate and pelvic-node models met predefined plan-quality, optimization-iteration, user-acceptance, and safety criteria; the summary does not publish all sample sizes or effect estimates.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA materials describe separate development, independent performance-verification, and four-site prospective U.S. clinical-validation datasets. Both prostate and pelvic-node models met predefined plan-quality, optimization-iteration, user-acceptance, and safety criteria; the summary does not publish all sample sizes or effect estimates.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Optimization-iteration reduction success criterion

20 %

  • EndpointRequired mean reduction with Dose+ assistance
  • PopulationDose+ (1.0)
  • Tested versionDose+ 1.0

K250064 FDA performance package for Dose+ (1.0)

  • DesignProspective within-subject assisted-versus-unassisted planning comparison with ABR-certified medical physicist validators
  • PopulationU.S. patients aged 60 years and older treated for prostate cancer, including prostate-only and pelvic-node models
  • Scopeexact submission
  • Tested versionDose+ 1.0
  • Sites4
  • IndependenceSponsor or vendor study

K250064

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K250064 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Patient CT images, RT Structure Sets, ROI names, and target dose prescription.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)

  2. Routing

    Source context, not route validation: DICOM-RT input and RT Dose export to compatible treatment-planning or review software; exact TPS compatibility requires acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0) · Dose+ product-family overview

  3. AI processing

    Source context, not route validation: K250064 describes cloud service with secure HTTPS transfer or local installation in the provider network.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0) · Dose+ product-family overview

  4. Returned objects

    Source context, not route validation: DICOM RT Dose object containing a predicted three-dimensional dose distribution.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)

  5. Viewer/worklist/report

    Unresolved route: DICOM RT Dose object containing a predicted three-dimensional dose distribution.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
K250064 describes cloud service with secure HTTPS transfer or local installation in the provider network.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM-RT input and RT Dose export to compatible treatment-planning or review software; exact TPS compatibility requires acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-03
Security
K250064 describes secure HTTPS transfer for cloud deployment. Current vendor material also describes pseudonymization and deletion controls; obtain exact-version architecture, retention, support-access, audit, and incident-response evidence before contracting.
  • Exact FDA submission
  • Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training
Only qualified radiation oncologists, medical physicists, and medical dosimetrists. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K250064 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM-RT input and RT Dose export to compatible treatment-planning or review software; exact TPS compatibility requires acceptance testing.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250064
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Prostate/Pelvis
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

Twenty PubMed records and ten trial records were screened. They concern dose, drugs, or radiotherapy generally and do not identify Dose+ 1.0/K250064 as the tested release. No evidence was promoted, and all 30 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision material, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K250064: Dose+ (1.0)

    U.S. Food and Drug Administration - Published 2025-09-04 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Dose+ product-family overview

    MVision AI - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, security, implementationCapabilities, currentCommercialContext

Research history

  1. K250064 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242822

ART-Plan+ (v.3.0.0)

Therapanacea SAS

Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-02-25
FDA-cleared K250035

Contour ProtégéAI+

MIM Software Inc.

Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Decision
2025-02-03
FDA-cleared K231765

Contour ProtégéAI

MIM Software Inc.

Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.

Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Decision
2023-11-08

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history